Feasibility Study of a Web-Based Automated Self-Administered 24-hour Dietary Recall (ASA 24) and a Physical Activity 24-hour Recall
Launched by NATIONAL CANCER INSTITUTE (NCI) · Jul 15, 2010
Trial Information
Current as of May 23, 2025
Completed
Keywords
ClinConnect Summary
In spite of long-standing hypothesis relating diet and physical activity to several cancers, diet and physical activity-cancer associations have been modest at best and often inconsistent in epidemiologic studies. Investigators around the world have become increasingly concerned that error in the measurement of both diet and physical activity is compromising our ability to detect these important but modest associations. Most commonly used diet and physical activity assessment methods have been based on a relatively small set of questions (e.g. 124 food items consumed or 5-10 physical activi...
Gender
ALL
Eligibility criteria
- • We will recruit 5,000 subjects from the existing NIH-AARP study participants who are currently 62 to 83 years old. To include individuals who are at least 50 years old, we will expand our recruitment effort to 10,000 new AARP members who are at least 50 years old and not currently NIH-AARP study cohort members. We will target individuals residing in one of the following states: Florida; Pennsylvania; New Jersey; Louisiana; North Carolina; California; Detroit; Michigan; and Atlanta, Georgia, Nevada, Arizona, Texas, Illinois, Washington, Wisconsin, Colorado, Connecticut, Kentucky, Utah and Massachusetts (subject to change due to availability of high-quality state cancer registries). The names and addresses of new AARP members will be provided by AARP.
About National Cancer Institute (Nci)
The National Cancer Institute (NCI) is a prominent component of the National Institutes of Health (NIH), dedicated to advancing cancer research and improving patient outcomes through innovative clinical trials. As a leading sponsor of cancer-related studies, NCI focuses on facilitating the development of new therapies, enhancing prevention strategies, and understanding the biology of cancer. The institute collaborates with academic institutions, healthcare providers, and industry partners to conduct rigorous clinical trials that aim to translate scientific discoveries into effective treatments. NCI’s commitment to fostering a robust research environment supports the mission to eliminate cancer as a major health problem.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bethesda, Maryland, United States
Patients applied
Trial Officials
Charles E Matthews, Ph.D.
Principal Investigator
National Cancer Institute (NCI)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials